Overview

• Novo Nordisk's experimental obesity drug CagriSema underperformed in late-stage trials, with weight-loss results falling short of earlier forecasts for both diabetic and non-diabetic patients.
• The company has lost significant market value, with its stock declining and SAP overtaking it as Europe's most valuable company.
• Novo Nordisk has acquired global rights to UBT251, a next-generation 'Triple G' obesity drug from United Laboratories International, in a deal worth up to $2 billion.
• UBT251 targets three gut hormones and has shown promising early trial results, potentially positioning Novo Nordisk to compete with Eli Lilly's upcoming retatrutide.
• The weight-loss drug market is projected to reach $100 billion by 2030, intensifying competition between Novo Nordisk, Eli Lilly, and other emerging players.